Abstract:AIM To evaluate bioequivalence of lansoprazole and its metabolites 5-hydroxy lansoprazole and lansoprazole sulphone in 22 healthy male vounteers after a single oral dose of 30 mg.METHODS LC:using Diamonsil C_(18) column(250 mm×2.1 mm,5 μm)with preliminary column Octadecy1 C_(18)(4.0 mm×3.05 mm);the mobile phase consiting of acetonitrile-2 mmol·L~(-1) ammonium acetate solution(60∶40,V/V);the flow rate was 0.2 mL·min~(-1);and the column temperature was 40℃.MS:using electrospray ionization (ESI),and selected ion mass spectral (m/z) 368.1/164.1 (lansoprazole),384.0/180.0 (5-hydroxylansoprazole),384/115.9 (lansoprazole sulphone),364.1/188.1(internal standard)to quantify.The plasma samples were treated with acetonitrile precipitation.RESULTS The pharmacokinetic parameters of lansoprazole (test) were:AUC:(12 989.16±13 356.96)μg·h·L~(-1),c_(max)(2 780±1 282)μg·L~(-1),t_(max):(1.73±0.74)h,T_(1/2):(2.74±2.01)h;5-hydroxy lansoprazole(test) were:AUC:(197.51±68.54)μg·h·L~(-1),c_(max):(73.45±39.09)μg·L~(-1),t_(max):(1.59±(0.76))h,T_(1/2):(3.26±1.97)h;lansoprazole sulphone (test) were:AUC:((1 496.74)±2 517.81)μg·h·L~(-1),c_(max):(160.75±146.12)μg·L~(-1),t_(max):(2.18±1.55)h,T_(1/2):(2.94±3.48)h.The pharmacokinetic parameters of lansoprazole (reference) were:AUC:(13 426.99±3 671.51)μg·h·L~(-1),c_(max):(2 945±(1 383))μg·L~(-1),t_(max):(1.90±0.63)h,T_(1/2):(2.53±2.06)h;5-hydroxy lansoprazole (reference) were:AUC:(211.77±(78.40))μg·h·L~(-1),c_(max):(77.70±43.78)μg·L~(-1),t_(max):(1.83±0.65),T_(1/2):(3.03±1.77)h;lansoprazole sulphone (reference) were:AUC:(1 510.80±2 525.48)μg·h·L~(-1),c_(max):(169.20±151.28)μg·L~(-1),t_(max):(2.27±1.37)h,T_(1/2):(2.64±2.96)h.There were no significant differences in all pharmacokinetic parameters between 2 capsules.(P>0.05).CONCLUSION The results of two one-side test show that 2 preparations are bioequivalent.

Study on Bioavailability of Pantoprazole Sodium Enteric - Coated Capsules in Healthy Volunteers

Bioequivalence of Pantoprazole Sodium Enteric-Coated Capsules in Human

Relative Bioavailability of Sodium Pantoprazole Enteric-Coated Micro-Pill Capsules in Human Subjects

Study on bioequivalence of cilostazol table in healthy volunteers

Study on Pharmacokinetics and Bioequivalence of Omeprazole Enteric - coated Capsules in Healthy Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioequivalence of Lansoprazole Enteric Caspsules in Healthy Volunteers

Studies on the Bioequivalence of Lorazepam Tablet in Healthy Volunteers

Pharmacokinetics and Relative Bioavailability of Omeprazole Capsule in HealthyVolunteers after a Single Oral Administration

LC Determination and Bioequivalence Study of Pantoprazole in Human Plasma

Quantification of Pantoprazole in Human Plasma Using LC-MS/MS for Pharmacokinetics and Bioequivalence Study

Bioequivalence Evaluation of Two Rabeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

Bioequivalence Study of Two Esomeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

[Bioequivalence of Tiopronin Enteric Capsules in Healthy Volunteers].

Study on bioequivalence of pravastatin sodium tablets in healthy volunteers

Bioequivalence of lansoprazole and its metabolites

Relative bioavailability of sodium valproate tablets in healthy volunteers

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Bioequivalence of ketoconazole capsules in Chinese healthy volunteers

Pharmacokinetics and Pharmacodynamics of Lansoprazole/Sodium Bicarbonate Immediate-release Capsules in Healthy Chinese Subjects: An Open, Randomized, Controlled, Crossover, Single-, and Multiple-dose Trial.

LC -MS/MS Determination of Pantoprazole Content in Human Plasma